{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:47Z","timestamp":1792601627688,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.pharmthera.2012.07.013","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T12:03:42Z","timestamp":1345809822000},"page":"334-342","source":"Crossref","is-referenced-by-count":327,"title":["Blinatumomab: A historical perspective"],"prefix":"10.1016","volume":"136","author":[{"given":"Dirk","family":"Nagorsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Baeuerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.07.013_bb0015","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/138920112800785005","article-title":"Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer","volume":"13","author":"Baeuerle","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0005","first-page":"22","article-title":"BiTE: Teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0010","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0260","series-title":"Bispecific antibodies","first-page":"273","article-title":"Bispecific T cell engager for cancer therapy","author":"Baeuerle","year":"2011"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","article-title":"Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation","volume":"23","author":"Baracho","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0030","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0035","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0040","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/14740338.2011.562188","article-title":"The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis","volume":"10","author":"Brinkman","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0050","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.leukres.2008.08.025","article-title":"Combination of rituximab with blinatumomab (MT103\/MEDI-538), a T cell-engaging CD19-\/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells","volume":"33","author":"d'Argouges","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0060","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3\u2010bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0070","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.soc.2007.08.004","article-title":"Tumor microenvironment and immune escape","volume":"16","author":"Ferrone","year":"2007","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/smim.1998.9999","article-title":"CD19 regulates B lymphocyte responses to transmembrane signals","volume":"10","author":"Fujimoto","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0080","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"Suppl. 4","key":"10.1016\/j.pharmthera.2012.07.013_bb0085","first-page":"iv104","article-title":"Blinatumomab (CD3\/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL","volume":"22","author":"Goebeler","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00262-003-0496-2","article-title":"T-cell-mediated lysis of B cells induced by a CD19\u00d7CD3 bispecific single-chain antibody is perforin dependent and death receptor independent","volume":"53","author":"Gruen","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.V72.1.299.299","article-title":"Asynchronous antigen expression in B lineage acute lymphoblastic leukemia","volume":"72","author":"Hurwitz","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0115","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0120","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1593\/neo.08570","article-title":"Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells","volume":"10","author":"Kischel","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0125","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2008.83","article-title":"CD34+CD38+CD19+ as well as CD34+CD38\u2212CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL","volume":"22","author":"Kong","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0130","first-page":"10","article-title":"Minimal costimulatory requirements for T cell priming and TH1 differentiation: Activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs","volume":"1","author":"Kufer","year":"2001","journal-title":"Cancer Immun"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0135","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"Loffler","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0140","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19\u00d7CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0145","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10555-011-9270-7","article-title":"Tumor immunosurveillance in human cancers","volume":"30","author":"Mlecnik","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0155","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"Molhoj","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0160","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0165","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10428190902943077","article-title":"Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab","volume":"50","author":"Nagorsen","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0170","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.4049\/jimmunol.138.9.2793","article-title":"CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation","volume":"138","author":"Pezzutto","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0175","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0185","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.seminoncol.2011.01.008","article-title":"Personalized treatment of lymphoma: Promise and reality","volume":"38","author":"Ramsdale","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0195","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/376352a0","article-title":"Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice","volume":"376","author":"Rickert","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0205","first-page":"1361","article-title":"Granzyme B-induced apoptosis in cancer cells and its regulation (review)","volume":"37","author":"Rousalova","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-005-0001-1","article-title":"T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"55","author":"Schlereth","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.seminhematol.2010.01.003","article-title":"Rituximab in indolent lymphomas","volume":"47","author":"Sousou","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0220","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0230","article-title":"Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: Updated results of an ongoing phase II trial","volume":"118","author":"Topp","year":"2011"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0225","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0235","article-title":"Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma","volume":"118","author":"Viardot","year":"2011"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0240","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","article-title":"CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma","volume":"13","author":"Wahlin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0245","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: Controversies in its development, utility and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2009.011726","article-title":"Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia","volume":"95","author":"Wilson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2012.07.013_bb0255","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T08:21:11Z","timestamp":1687681271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0163725812001830"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.07.013","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}